Q-omics provides the consensus-scored UNC45B profile across patient tissues and cancer cell-line models. UNC45B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, UNC45B is differentially expressed in 10, with the highest sampling consensus in LUAD. Additionally, UNC45B RNA expression shows 14,784 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, LUAD, and TGCT as cancer lineages where UNC45B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UNC45B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UNC45B survival associations across molecular data types. UNC45B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (11) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UNC45B RNA expression–survival associations across cancer types. High UNC45B expression shows unfavorable associations in KIRP, UVM, ACC, BLCA and MESO, but favorable associations in LUAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for UNC45B RNA expression.
This table summarizes UNC45B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 3. The strongest signals are observed in LUAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for UNC45B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UNC45B shows lower tumor expression in LUAD, KICH, LUSC, KIRP, THCA and HNSC. The LUAD box plot shows higher UNC45B RNA expression in normal versus tumor tissue (log2 FC = −0.877, t-test p < 0.001).
This table shows molecular features associated with UNC45B in patient tissues and cancer cell lines. In patient samples, UNC45B shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, UNC45B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
